In the latest session, Incyte Corp. (NASDAQ: INCY) closed at $57.72 down -0.89% from its previous closing price of $58.24. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 1535568 shares were traded.
Ratios:
For a deeper understanding of Incyte Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.93. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on February 23, 2024, initiated with a Buy rating and assigned the stock a target price of $81.
Leerink Partners Upgraded its Market Perform to Outperform on December 13, 2023, while the target price for the stock was maintained at $78.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 03 ’24 when Stein Steven H sold 7,365 shares for $65.51 per share. The transaction valued at 482,481 led to the insider holds 90,218 shares of the business.
Iyengar Vijay K sold 657 shares of INCY for $42,705 on Jan 02 ’24. The EVP, GMAPPS now owns 43,412 shares after completing the transaction at $65.00 per share. On Dec 13 ’23, another insider, Tray Thomas, who serves as the Principal Accounting Officer of the company, sold 1,067 shares for $62.37 each. As a result, the insider received 66,549 and left with 23,436 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 12.96B and an Enterprise Value of 9.34B. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.82, and their Forward P/E ratio for the next fiscal year is 10.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.51 while its Price-to-Book (P/B) ratio in mrq is 2.49. Its current Enterprise Value per Revenue stands at 2.53 whereas that against EBITDA is 10.16.
Stock Price History:
Over the past 52 weeks, INCY has reached a high of $76.04, while it has fallen to a 52-week low of $50.27. The 50-Day Moving Average of the stock is 59.67, while the 200-Day Moving Average is calculated to be 60.13.
Shares Statistics:
For the past three months, INCY has traded an average of 1.70M shares per day and 2.04M over the past ten days. A total of 224.29M shares are outstanding, with a floating share count of 221.85M. Insiders hold about 1.19% of the company’s shares, while institutions hold 99.08% stake in the company. Shares short for INCY as of Feb 29, 2024 were 7.77M with a Short Ratio of 4.58, compared to 6.98M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.46% and a Short% of Float of 4.15%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.87 for the current quarter, with a high estimate of $1.21 and a low estimate of $0.6, while EPS last year was $0.37. The consensus estimate for the next quarter is $1.16, with high estimates of $1.28 and low estimates of $0.99.
Analysts are recommending an EPS of between $5.8 and $3.59 for the fiscal current year, implying an average EPS of $4.59. EPS for the following year is $5.46, with 14 analysts recommending between $6.88 and $3.61.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $932.42M this quarter.It ranges from a high estimate of $990M to a low estimate of $870.46M. As of the current estimate, Incyte Corp.’s year-ago sales were $859.17M, an estimated increase of 8.50% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $1.03B, an increase of 7.60% less than the figure of $8.50% in the same quarter last year. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $994.1M.
A total of 17 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.27B, while the lowest revenue estimate was $3.99B, resulting in an average revenue estimate of $4.15B. In the same quarter a year ago, actual revenue was $3.7B, up 12.30% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $4.59B in the next fiscal year. The high estimate is $4.83B and the low estimate is $4.18B. The average revenue growth estimate for next year is up 10.70% from the average revenue estimate for this year.
